ICOS

ICOS

ICOS Overview

Molecule Name
Inducible T-cell costimulator
Synonyms
ICOS,CD278,AILIM,Inducible T-cell costimulator
Drug Development Progress
Drugs in Clinical Trials7
Approved Drugs0
Highest Development StagePhase 2 Clinical
Target Synonym
Activation-inducible lymphocyte immunomediatory molecule,Inducible T-cell costimulator,ICOS,CD278,AILIM,Inducible T Cell Costimulator,Inducible T-Cell Co-Stimulator,Inducible Costimulator,CD278 Antigen,CVID1,Inducible T-Cell Co-Stimulator Protein
Background
Inducible T-cell costimulator (ICOS) is also known as Activation-inducible lymphocyte immunomediatory molecule (AILIM), CD278, which belongs to the CD28 family of immune costimulatory receptors consisting of CD28, CTLA-4 and PD-1. ICOS enhances all basic T-cell responses to a foreign antigen, namely proliferation, secretion of lymphokines, up-regulation of molecules that mediate cell-cell interaction, and effective help for antibody secretion by B-cells. CD278 / ICOS prevents the apoptosis of pre-activated T-cells and also plays a critical role in CD40-mediated class switching of immunoglobin isotypes.

ICOS Product List

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
VopratelimabJTX-2011Phase 2 ClinicalJounce Therapeutics Inc
Carcinoma, Non-Small-Cell Lung; Neoplasms
Details
FeladilimabGSK-609; GSK-3359609Phase 2 ClinicalGlaxosmithkline Plc
Head and Neck Neoplasms; Multiple Myeloma; Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck
Details
AcazicolceptALPN-101Phase 2 ClinicalAlpine Immune Sciences Inc
Autoimmune Diseases; Graft vs Host Disease; Inflammation; Lupus Erythematosus, Systemic; Lymphoproliferative Disorders
Details
MEDI-570Phase 1 ClinicalJapan Tobacco (Hong Kong) Ltd
Lupus Erythematosus, Systemic; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides
Details
IzuralimabXmAb-23104; XmAb-104Phase 1 ClinicalXencor Inc
Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Endometrial Neoplasms; Gastroesophageal Junction Neoplasms; Melanoma; Nasopharyngeal Carcinoma; Pancreatic Neoplasms; Sarcoma; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms
Details
Anti-ICOS (Bristol Myers Squibb)BMS-986226Phase 1 ClinicalBristol-Myers Squibb Company
Neoplasms
Details
anti-ICOS mAb (Bristol-Myers Squibb)Phase 1 ClinicalBristol-Myers Squibb Company
Neoplasms; Solid tumours
Details